Why is NOAEL considered a limitation in risk assessment compared to BMD approaches?

• A. Because it depends on the dose spacing used in the study.
• B. Because it uses all data points to model the curve.
• C. Because it provides the most protective estimate.
• D. Because it is always lower than LOAEL.

Answer: (A)

The main idea is that NOAEL’s value is tied to how the study chose and spaced the doses. Because NOAEL is simply the highest dose at which no adverse effect was observed, it can shift depending on which dose levels were tested and how close they are to where effects begin. If the dose grid is sparse or if the true threshold falls between tested doses, the NOAEL may not reflect the real point at which problems start, and it provides little information about the overall dose–response or uncertainty. Benchmark Dose approaches avoid this by fitting a dose–response model to all data points, estimating the dose that corresponds to a predefined effect, and giving confidence limits around that estimate. This makes the point of departure less dependent on arbitrary dose spacing and yields a more robust, quantitative basis for risk assessment.